Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen. ... In the EU, Erleada is approved for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic

Latest news

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....